Cheryl A. Thompson

Learn More
1890 Am J Health-Syst Pharm—Vol 66 Nov 1, 2009 FDA approves pralatrexate for treatment of rare lymphoma P ralatrexate, a metabolic inhibitor that resembles folic acid, has been approved for the treatment of peripheral T-cell lymphoma in patients whose disease has returned or not responded to other therapy, FDA and Allos Therapeutics Inc. announced September(More)